Cardiorenal metabolic syndrome: A clinical case of a multimorbid patient and rationale for cardio- and nephroprotective therapy
Open Access
- 11 July 2026
- journal article
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 7 (2) , 79-84
Abstract
Кардио-рено-метаболический синдром: мультиморбидный пациент и стратегия кардио- и нефропротекцииKeywords
This publication has 18 references indexed in Scilit:
- Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World StudyThe American Journal of Cardiology, 2026
- NEJM at ESC — Finerenone in Heart Failure for Mildly Reduced or Preserved Ejection FractionNew England Journal of Medicine, 2024
- Diabetic Myocardial Disorder. A Clinical Consensus Statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial DiseasesEuropean Journal of Heart Failure, 2024
- Low Utilization of Lead Extraction Among Patients With Infective Endocarditis and Implanted Cardiac Electronic DevicesJACC, 2023
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsThe Lancet, 2020
- Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve ReplacementJACC, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015